MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH
MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), or metastatic colorectal cancer (mCRC)
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
P3-IMU-838-RMS-02 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
P3-IMU-838-RMS-01 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ADAPTIVE PHASE III TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF VILOBELIMAB IN THE TREATMENT OF ULCERATIVE PYODERMA GANGRENOSUM
Sponsor InflaRx GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH?
The 2026-10-09 snapshot links MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH to 8 distinct CTIS trials. Recorded services include Laboratory services, PK data analysis and modelling, Analysis of C5a and IFX-1. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH?
The most frequently recorded therapeutic areas are Immunology, Neurology, Solid Tumor Oncology, Gastroenterology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH conducted?
The linked trials record locations in 22 countries, including Germany, Poland, Belgium, Bulgaria, Spain. These are trial locations, not confirmed office locations or countries where MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH delivered services.
What can this page tell me about MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- MENAL Gesellschaft fuer medizinische und naturwissenschaftliche Laboranalytik mbH